Continuing Medical Education Information

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. Neurofibromatosis in Neuro-Oncology Advances

needs of neuro-oncologists.It may also be of benefit to other clinicians interested or involved in the treatment of patients with neurofibromatosis.

Learning Objectives
Upon proper completion of this activity, participants should be better able to:

Disclosure of Commercial Support
This activity is supported by an educational grant from AstraZeneca.

Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest.Conflicts, if any, are resolved through one or more processes.All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME's Standards for Commercial Support of Continuing Medical Education.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC.Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements.However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC's activities must include a balanced view of therapeutic options.Use of generic names contributes to this impartiality.The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

Terms of Use and Privacy Policy Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional.This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC.References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC.Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program.Required items include first name, last name, degree, and email address.These items are necessary.Participants are also required to complete an evaluation of the CME activity.All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties.Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process.Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants' credits.

Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.

•
Describe the relevance of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitors • Interpret efficacy and safety data from the latest clinical trials investigating MEK inhibitors for treatment of neurofibromas • Describe the molecular drivers for the spectrum of tumors in NF1 • Assess the development of potential targeted therapies for the spectrum of tumors in NF1 • Describe the importance of developing new measures of quality of life to facilitate the design of clinical trials in NF1 Physician Accreditation Statement Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Physician Credit Designation Statement Paradigm Medical Communications, LLC designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.